A medical team at Cooper University Health Care recently was the first in the eastern United States to treat a patient with central sleep apnea (CSA) with a new implantable device to stimulate breathing. Cooper is currently one of only 24 sites in the United States treating CSA with the remedē^® System, developed by medical technology company Respicardia, Inc. The remedē^® System received FDA-approval in 2017 and is the first commercially available device to treat CSA. Read more.

The Coriell Institute for Medical Research, Cooper University Health Care and Cooper Medical School of Rowan University (CMSRU) are launching the Camden Opioid Research Initiative (CORI), a first-of-its-kind undertaking to investigate the genetic and biological factors that contribute to the development of opioid use disorder (also referred to as opioid dependence or addiction). Opioid overdoses continue to climb in New Jersey and nationally and the opioid addiction epidemic is one of the most urgent public health concerns of our time. Read more.

Study explores if some patients may forego surgery after chemotherapy

MD Anderson Cancer Center at Cooper has joined a clinical research study to determine if certain breast cancer patients who respond positively to neoadjuvant systemic therapy can be treated without surgery. This study, done in conjunction with The University of Texas MD Anderson Cancer Center in Houston, is led by principal investigator Henry M. Read more.

Cooper University Health Care is one of only 24 sites in the United States currently treating patients with central sleep apnea (CSA) with a new implantable device to stimulate breathing. The remedē^® System, developed by medical technology company Respicardia, Inc., received FDA-approval in 2017 and is the first commercially available device to treat CSA.

“CSA is a serious breathing disorder that disrupts the normal breathing pattern during sleep and negatively affects quality of life and overall cardiovascular health,” said John A. Read more.